A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD
- Resource Type
- Article
- Source
- In
Respiratory Medicine February 2017 123:8-17 - Subject
- Language
- ISSN
- 0954-6111